breast tumors

Related by string. Breast Tumors * breasts . breasted . Breasts . Breast . BREAST . Breasted : Breast Cancer Awareness Month . San Antonio Breast Cancer . Breast Cancer Campaign . Breast Cancer Patients . breast cancer survivors . breast cancer survivor / Tumor . Tumors . TUMOR . TUMORS : malignant brain tumor . cancerous brain tumor . battling brain tumor . brain tumor . cancerous tumor removed * *

Related by context. All words. (Click for frequent words.) 82 tumors 76 lung tumors 75 breast cancers 73 prostate cancers 71 prostate tumors 70 tumor 70 ovarian tumors 68 pancreatic cancers 67 colorectal tumors 67 pancreatic tumors 67 lung cancers 66 melanoma tumors 66 bladder cancers 66 prostate tumor 66 ovarian cancers 66 tumor cells 65 cancers 65 malignant tumors 65 metastases 65 ovarian cancer 65 metastatic tumors 65 endometrial cancers 65 colorectal cancers 64 colon tumors 64 metastatic prostate cancer 64 prostate tissue 64 adenoma 64 micrometastases 64 endometrial cancer 64 melanoma 64 colorectal cancer 64 melanomas 64 breast lesions 63 cancerous tumors 63 atypical hyperplasia 63 adenocarcinoma 63 lobular carcinoma 63 HER2 positive 63 pancreatic tumor 63 breast carcinomas 62 metastatic lesions 62 mammary tumors 62 malignancy 62 breast carcinoma 62 carcinoma 62 estrogen receptor negative 62 glioblastomas 62 cancerous cells 62 Tumours 62 adenomas 62 malignant cells 62 metastatic 62 breast tissue 62 metastatic cancer 62 metastasis 61 pancreatic adenocarcinoma 61 HER2 positive breast cancer 61 HER2 positive tumors 61 PCa 61 liver metastases 61 glioblastoma 61 adenocarcinomas 61 mammary cancers 61 breast cancer recurrence 61 medulloblastoma 61 HER2 61 Tumors 61 invasive breast cancer 61 GBM tumors 61 GISTs 60 axillary lymph nodes 60 malignant growths 60 colon cancers 60 pre cancerous lesions 60 ovarian tumor 60 DCIS 60 metastatic disease 60 tumor recurrence 60 breast cancer 60 lymph node metastases 60 ductal breast cancer 60 prostate cancer 60 bowel cancers 60 glioblastoma tumors 60 EGFR 60 colon cancer 60 colon polyps 59 EGFR mutation 59 atherosclerotic lesions 59 bladder tumors 59 gastric cancers 59 malignancies 59 invasive carcinoma 59 neuroendocrine tumors 59 carcinomas 59 NSCLC 59 gene amplification 59 factor receptor 59 squamous cell carcinomas 59 HER2 protein 59 colorectal polyps 59 renal cell carcinomas 59 brain tumors 59 anaplastic 59 metastatic melanomas 59 cervical lesions 59 malignant prostate 59 estrogen receptor positive 59 ErbB2 59 prostate cancer PCa 59 distant metastases 58 estrogen receptors 58 IGF 1R 58 basal cell carcinomas 58 mammary cells 58 pre cancerous cells 58 nonmelanoma skin cancers 58 seminoma 58 aromatase 58 mesothelin 58 intestinal polyps 58 precancerous growths 58 malignant lesions 58 gliomas 58 cisplatin resistant 58 EGFRvIII 58 lung metastases 58 fibroadenomas 58 colorectal cancer CRC 58 lymphomas 58 estrogen receptor ER 58 pre cancerous polyps 58 colorectal carcinoma 58 ductal cancer 58 lung nodules 58 BRCA mutations 58 HER2 receptor 58 sarcosine 58 ductal carcinomas 58 benign polyps 58 precancerous lesions 58 lung adenocarcinoma 58 NSCLC tumors 58 hormone receptor positive 58 hypermethylation 58 benign growths 58 neuroblastomas 58 lung metastasis 58 GIST tumors 58 lobular cancer 58 neoplasia 58 premalignant lesions 58 advanced adenomas 58 medulloblastomas 58 HNSCC 58 distant metastasis 58 ovarian carcinoma 58 metastatic breast cancer 58 CaP 58 BRAF mutation 58 atypia 58 lymph nodes 58 HER2 negative 58 EGFR mutations 58 c MYC 57 precursor lesions 57 fibroids 57 neoplasms 57 renal tumors 57 ductal carcinoma 57 CLL cells 57 lung adenocarcinomas 57 operable breast cancer 57 estrogen receptor 57 tamoxifen 57 HER2 gene 57 autoantibodies 57 HER2 positive cancers 57 ductal adenocarcinoma 57 glioblastoma cells 57 p# mutations 57 precancerous cells 57 sentinel nodes 57 breast epithelial cells 57 pre cancerous growths 57 precancerous 57 lung cancer 57 ependymoma 57 EGFR gene 57 tumor suppressor gene 57 CIN2 + 57 endostatin 57 BRAF gene 57 brain metastases 57 nonsmall cell lung cancer 57 poorer prognosis 57 renal cell carcinoma 57 malignant lymphoma 57 lobular breast cancer 57 breast cancer metastasis 57 HPV infections 57 invasive cervical cancer 57 endometrial 57 occult metastases 57 malignant melanoma 57 epithelial ovarian cancer 57 peritoneal carcinomatosis 57 BRCA1 gene 57 pulmonary metastases 57 uterine cancers 57 PGE2 57 uveal melanoma 57 hamartomas 57 curable cancers 57 Her2 57 gastric cancer 57 grade gliomas 57 endometrial hyperplasia 56 hereditary breast cancer 56 malignant nodules 56 BRCA mutation carriers 56 bladder cancer 56 incidentalomas 56 Stat5 56 cell lung cancer 56 EGFR protein 56 bone metastasis 56 osteosarcomas 56 pituitary tumors 56 recurrent ovarian cancer 56 prostate cancer CaP 56 WT1 56 cancerous lesions 56 HER2/neu 56 ovarian 56 hypermethylated 56 lymph node 56 prostate carcinoma 56 basal cell carcinoma BCC 56 seminomas 56 premalignant 56 androgen receptor 56 lung carcinomas 56 micrometastasis 56 carcinoid 56 liver metastasis 56 squamous cell 56 suppresses tumor 56 situ LCIS 56 progesterone receptor negative 56 prostate adenocarcinoma 56 epithelial tumors 56 tumor subtypes 56 hepatocellular carcinoma HCC 56 tumor progression 56 beta1 integrin 56 pancreatic cancer 56 node metastases 56 PARP inhibitors 56 glandular tissue 56 B7 H3 56 serous ovarian cancer 56 FGFR2 56 colorectal tumor 56 hedgehog pathway 56 endometrial tumors 56 cutaneous melanoma 56 mammographic density 56 papillary 56 PKCi 56 rectal cancers 56 leukemic cells 56 carcinoid tumor 56 cell carcinoma 56 uPAR 56 tumor xenografts 56 OGG1 56 malignant melanomas 56 pCR 56 benign tumors 56 urothelial carcinoma 56 myeloma cells 56 thyroid nodules 56 pancreatic lung 56 mutant protein 56 aneuploid cells 56 xenograft tumors 55 telomere lengths 55 BRCA2 55 epithelial ovarian 55 GSTP1 55 nodal metastasis 55 hepatocellular carcinoma 55 BRCA1 mutations 55 cyclin E 55 carcinoid tumors 55 p# mutation 55 sentinel lymph node biopsy 55 BRCA deficient 55 mutated genes 55 KRAS mutation 55 malignant pleural mesothelioma 55 medullary thyroid cancer 55 prostate specific 55 molecular abnormalities 55 neuroblastoma tumors 55 metastatic tumor 55 sentinel node 55 abnormal cervical 55 sarcoma 55 endometrial cells 55 Akt1 55 axillary nodes 55 NF kB pathway 55 TGF β 55 MAGE A3 55 cancerous tissue 55 lymph node involvement 55 colorectal adenomas 55 oncogene 55 gastrointestinal stromal tumors 55 mesotheliomas 55 micro RNAs 55 localized prostate cancer 55 basal cell nevus syndrome 55 ZNF# 55 clusterin 55 malignant transformation 55 uterine tumors 55 leukaemias 55 Carcinoid tumors 55 tumor suppressor genes 55 mucinous 55 HGPIN 55 contralateral breast 55 leiomyomas 55 glioblastoma tumor 55 imatinib Gleevec 55 AGTR1 55 egg follicles 55 cancerous breast 55 hormone estrogen 55 neuroblastoma cells 55 epidermal growth 55 metastatic lesion 55 STAT3 55 benign lesions 55 differentiated thyroid 55 colorectal polyp 55 skin cancers 55 esophageal adenocarcinoma 55 ERCC1 55 thyroid cancers 55 lymph node metastasis 55 androgen receptors 54 axillary dissection 54 IDH1 mutation 54 invasive ductal carcinoma 54 KRAS mutations 54 cyclin D1 54 EUS FNA 54 tumorigenic 54 basal cells 54 trophoblasts 54 abnormal growths 54 thyroid tumors 54 tumor shrinkage 54 invasive ductal 54 PSADT 54 breast ovarian 54 chromosomal abnormalities 54 EGF receptors 54 Cholangiocarcinoma 54 Barrett esophagus 54 squamous cell lung cancer 54 precancerous polyp 54 Malignant tumors 54 noncancerous cells 54 BRAF mutations 54 advanced adenoma 54 thyroglobulin 54 Polyps 54 mesenchymal cells 54 pre cancerous 54 polyps 54 familial pancreatic cancer 54 ALCL 54 cell carcinomas 54 Cancerous cells 54 specific antigen 54 genes BRCA1 54 follicular lymphoma 54 EGFr 54 aneuploidy 54 olaparib 54 ovarian lung 54 lesions 54 tumor biopsies 54 mutations 54 TOP2A 54 iNOS 54 PTEN gene 54 primary cilia 54 oropharyngeal cancer 54 renal carcinoma 54 Wilms tumor 54 breast cancer subtypes 54 precancers 54 squamous cell carcinoma SCC 54 pre cancerous lesion 54 glioma tumors 54 HER2 expression 54 hormonal therapy 54 endometrial carcinoma 54 neoadjuvant therapy 54 ADPKD 54 lymphoma 54 PIK3CA 54 overexpress 54 somatic mutations 54 cell lymphomas 54 SETDB1 54 EpCAM 54 papillary carcinoma 54 benign breast 54 myeloid cells 54 brain lesions 54 pre malignant lesions 54 epithelial cancers 54 MGUS 54 mTOR inhibitors 54 urothelial cancer 54 endocrine tumors 54 FGFR1 54 micronuclei 54 epithelial tissues 54 NF1 54 superficial bladder cancer 54 luminal cells 54 GRP# 54 metastatic melanoma 54 pancreatic carcinoma 54 activating mutations 54 methylation patterns 54 lobular carcinomas 54 neuroendocrine carcinoma 54 glioma 54 liver cancer 54 hepatoma 54 hTERT 54 mutated protein 54 Hepatocellular Carcinoma HCC 54 recurrent ovarian 54 K ras mutations 54 squamous cell cancers 54 histopathologic examination 54 nutlin 3a 54 HER2 receptors 53 Papillary 53 CDK4 53 JMML 53 KRAS oncogene 53 metastatic renal cell carcinoma 53 lobular 53 male hormones androgens 53 miRNA genes 53 basal cell carcinoma 53 squamous cell carcinoma 53 cancerous growths 53 fibroadenoma 53 oncoprotein 53 basal cell cancers 53 noncancerous tumors 53 HMGA2 53 solid tumors 53 androgen receptor AR 53 activin 53 premenopausal breast cancer 53 TAp# 53 neoplastic cells 53 gene mutations 53 PTEN protein 53 gene mutation 53 ductal 53 melanoma lesions 53 breast endometrial 53 neurofibromas 53 estrogen receptor progesterone receptor 53 hyperplastic 53 EZH2 53 lymphatic tissue 53 GLI1 53 spontaneously regress 53 colorectal liver metastases 53 adenomatous 53 cervical carcinoma 53 GSTT1 53 caveolin 1 53 denser breasts 53 LRP6 53 atypical ductal hyperplasia 53 MSMB 53 HPV# 53 adenomatous polyps 53 BRAF V#E mutation 53 polycystic ovary syndrome PCOS 53 malignant tissue 53 invasive lobular carcinoma 53 genetic alteration 53 gastrointestinal stromal tumor GIST 53 Glioblastoma 53 ovaries 53 metastatic cancers 53 gastrointestinal GI cancers 53 skeletal metastases 53 miRNA expression 53 MDSCs 53 cisplatin 53 IGF IR 53 PARP inhibition 53 cancer 53 genetic alterations 53 carcinogenesis 53 Metastatic 53 synovial sarcoma 53 SATB1 53 PARP inhibitor 53 trophoblast cells 53 microcalcifications 53 miRNAs 53 metastatic prostate 53 adjuvant therapy 53 hormone LHRH 53 IFNg 53 Rectal cancer 53 tumor histology 53 tumoral 53 testicular cancers 53 chemopreventive agent 53 aromatase inhibitors 53 Carcinoma 53 oophorectomy 53 germline stem cells 53 CMV infection 53 lymphoid cells 53 leukemic cell 53 HER2 neu 53 angiogenesis inhibitor 53 vimentin 53 neoplasm 53 neuroblastoma 53 pancreatic 53 gastric adenocarcinoma 53 postmenopausal breast cancer 53 adrenal cortex 53 Clusterin 53 TET2 53 BRCA1 53 genistein 53 E#F# 53 neoplastic 53 cancerdefine 53 biopsies 53 pDCs 53 astrocytoma 53 HPV infection 53 blastomeres 53 prostate cancer metastases 53 gastric carcinoma 53 histological subtype 53 IGFBP 53 neoadjuvant chemotherapy 53 prostate cancer AIPC 53 testicular germ cell 53 gastrointestinal stromal tumors GIST 53 prostate glands 53 preoperative chemotherapy 53 FLT3 53 precancer 53 colorectal gastric 53 prostate 53 situ DCIS 53 Endometrial 53 RBP4 53 axillary lymph node dissection 53 PGDH 53 HER2 + 53 micro calcifications 53 mesothelial cells 53 pituitary hormones 53 sentinel node biopsy 53 MUC1 53 mtDNA mutations 53 fibroid 53 NF kB 53 p# protein 52 polycystic ovarian syndrome PCOS 52 precancerous tissues 52 metachronous 52 liver fibrosis 52 52 colorectal neoplasms 52 gene expression profiles 52 adenomatous polyp 52 prostate pancreatic 52 SPINK1 52 HER2 overexpression 52 basal cell cancer 52 Foxp3 52 genetic mutations 52 miR #b [001] 52 HbF 52 oesophageal cancer 52 genomic alterations 52 Acoustic neuromas 52 cancerous polyps 52 antigen PSA 52 castration resistant prostate cancer 52 bicalutamide 52 myocytes 52 Smad7 52 IDH2 52 teratoma 52 malignant polyps 52 sarcomas 52 disease progression 52 NEDD9 52 NKX2 52 androgens 52 MSH2 52 precancerous polyps 52 Zolinza 52 biopsied tissue 52 pituitary adenomas 52 choroidal melanoma 52 GNAQ 52 HER2 amplification 52 EGF receptor 52 papillary thyroid cancer 52 nodular melanoma 52 lymphangiogenesis 52 RKIP 52 GnRH agonists 52 benign nodules 52 coding genes 52 EGFR receptor 52 leukaemic stem cells 52 basal cell skin 52 MYCN amplification 52 breast biopsies 52 Wwox 52 TGF ß 52 mutated BRAF gene 52 microRNA molecules 52 chronic lymphocytic leukemia CLL 52 anaplastic lymphoma kinase 52 fine needle aspiration 52 MAPK pathway 52 promoter methylation 52 BACE1 52 EGFR mutant 52 MIF protein 52 Her2/neu 52 EGFR inhibitors 52 neoplasias 52 antisense inhibition 52 ErbB2 positive 52 sentinel lymph nodes 52 proto oncogene 52 chromosome aberrations 52 Sertoli cells 52 Melanomas 52 NKT cells 52 prognostic factor 52 paraganglioma 52 lesion 52 MALT lymphoma 52 cardiac progenitor cells 52 BRAF protein 52 telomerase inhibition 52 adipocyte differentiation 52 nestin 52 androgen 52 IDH1 52 cystectomy 52 mammographically 52 chromosomal aberrations 52 trastuzumab 52 VEGF expression 52 endometrium 52 paragangliomas 52 noncoding RNAs 52 DLBCL 52 hyperplasia 52 Getzenberg 52 epigenetic mechanisms 52 erlotinib 52 Bcr Abl 52 genetic abnormalities 52 Notch pathway 52 medically inoperable 52 pro angiogenic 52 BCR ABL 52 ALK mutations 52 glioma cells 52 pre menopausal 52 FDG PET 52 leiomyoma 52 TGFBR1 * 6A 52 prognostic indicator 52 hepatocellular carcinomas 52 contralateral breast cancer 52 ERBB2 52 sarcomatoid 52 TGF ß1 52 neural cells 52 impair fertility 52 metastatic colon cancer 52 underarm lymph nodes 52 dysplasia 52 K ras 52 microRNA miR 52 chromosomal rearrangement 52 VEGFR 52 microsatellite instability 52 RIP1 52 chemo resistant 52 fulvestrant 52 schwannomas 52 mutated KRAS gene 52 transgenic rats 52 melanocytic nevi 52 neovascularization 52 CagA 52 thyrotropin 52 anti angiogenic drugs 52 MDM2 52 xenografts 52 gastrointestinal cancers 52 anal lesions 52 BRCA mutation 52 meningioma 52 FGFR3 52 hippocampal neurons 52 Akt 52 esophageal squamous cell carcinoma 52 EBRT 52 BRCA1 mutation carriers 52 chromosomal instability 52 prostate specific antigen 52 relapsed ovarian cancer 52 chromosomal mutations 52 plasma kallikrein 52 prostate gland 52 precancerous cervical lesions 52 CGG repeats 52 microglial 52 mutated BRCA1 52 antiestrogen 52 Gleevec resistant 52 invasive carcinomas 52 gene variants 51 tissue biopsies 51 germ cells 51 BMP4 51 GRK2 51 biochemical recurrence 51 pelvic lymph nodes 51 estrogen receptor alpha 51 pheochromocytomas 51 neurofibroma 51 metastatic lung cancer 51 SUVmax 51 PrPSc 51 cervical lymph nodes 51 tumor regression 51 Uterine fibroids 51 gefitinib Iressa 51 glioblastoma multiforme 51 Breast Tumors 51 meningiomas 51 Vorinostat 51 amyloid deposits 51 premenopausal 51 beta subunit 51 Lodamin 51 metastatic lymph nodes 51 FGF# 51 papillomas 51 immunohistochemical staining 51 ARF1 51 circulating EPCs 51 prostate epithelial cells 51 MMP9 51 CCN2 51 dutasteride 51 germline mutations 51 peritoneal cancer 51 pleiotrophin 51 transthyretin 51 hormonal therapies 51 Peutz Jeghers syndrome 51 NFκB 51 armpit lymph nodes 51 ASCUS 51 endometrial tissue 51 androgen deprivation 51 transfected cells 51 thermogram 51 ovulatory cycles 51 squamous cell cancer 51 metastatic colorectal 51 estrogen therapy 51 chlamydial infection 51 genetic mutation 51 overexpressed 51 PSA velocity 51 LQTS 51 radiotracer 51 HPV 51 mosaicism 51 HER-2/neu 51 lobules 51 endocrine therapy 51 poly ADP ribose polymerase 51 Glioma 51 enzyme aromatase 51 invasive ductal carcinomas 51 Dr. Victor Velculescu 51 ovary 51 inhibitory effects 51 neuroblastoma tumor 51 NRG1 51 KIT mutations 51 anastrozole 51 estrogen receptor beta 51 Her-2/neu 51 cultured cells 51 BRCA2 mutations 51 colorectal carcinomas 51 imatinib 51 angiosarcoma 51 recurrent prostate cancer 51 oral squamous cell 51 liposarcoma 51 Id1 51 TGF beta 51 BRCA2 gene 51 PC3 cells 51 microRNAs 51 oncogenic HPV types 51 sentinel lymph node 51 abiraterone 51 hematopoietic cells 51 urothelium 51 micro RNA 51 ccRCC 51 hyperplastic polyps 51 breast cancer recurrences 51 senescent cells 51 LRP5 51 acute myelogenous leukemia AML 51 BRCA2 mutation 51 gene rearrangements 51 specific antigen PSA 51 uterine cancer 51 ependymomas 51 hormone deprivation 51 forskolin 51 Metastases 51 colorectal 51 hepatocellular cancer 51 Lymph node 51 colorectal adenoma 51 oesophageal adenocarcinoma 51 DCIS lesions 51 PCA3 gene 51 S#A# [002] 51 estrogen 51 BRCA2 mutation carriers 51 prostate cancer CRPC 51 BRCA1 mutation 51 FCGR3A 51 lung fibroblasts 51 lymphocytes 51 HER2 ErbB2 51 esophageal tumors 51 PKM2 51 choriocarcinoma 51 gefitinib 51 ALDH 51 keloid 51 squamous cells 51 paricalcitol 51 lymphoid tissue 51 radiosensitivity 51 BRCA2 carriers 51 Bcl xL 51 abnormal mammograms 51 gastrointestinal stromal tumors GISTs 51 suppressor cells 51 estrogen progesterone 51 oncomodulin 51 GBV C 51 NMIBC 51 Gliomas 51 prognostic variables 51 dysplastic nevi 51 miR #a [001] 51 atherosclerotic plaques 51 acinar 51 GATA3 51 F FDG PET 51 carcinoid cancer 51 breast lumps 51 palladin 51 leukemia ALL 51 narcolepsy cataplexy 51 taxane therapy 51 periodontitis 51 luteinizing hormone releasing 51 oncoproteins 51 MUC1 * 51 neuroendocrine cancers 51 testis 51 P selectin 51 precancerous spots 51 nanomolar 51 amyloid β 51 colon carcinoma 51 pRb 51 flavopiridol 51 papilloma 51 ERa 51 precancerous condition 51 tamoxifen therapy 51 fascin 51 Glioblastoma multiforme 51 JAK2 51 eccrine 51 CatB 51 calcitriol 51 cystic lesions 51 prognostic significance 51 Cyclin D1 51 HER2 positive metastatic breast 51 oligodendrogliomas 51 mammary stem cells 51 TGF beta signaling 51 autoantibody 51 CHD5 51 Immunohistochemical analysis 51 H. pylori eradication 51 lung carcinoma 51 RANKL 51 rectal cancer 51 commonly mutated genes 51 HER2 positive breast 51 hypomethylation 51 LHRH receptor positive 51 CXCL5 51 alveolar rhabdomyosarcoma 51 nasopharyngeal carcinoma 51 DCIS ductal carcinoma 51 gene BRCA2 51 VEGF receptor 51 endometrial lining 51 VEGFR2 51 Hedgehog pathway 51 rectal carcinoma 51 Smac mimetic 51 CEACAM1 51 NFkB 51 Glioblastomas 51 CD# protein 51 molecularly targeted 51 estrogen hormone 51 EphA2 50 NAFLD 50 mutant BRAF 50 cancerous 50 HGPS 50 KLF4 50 inherited mutations 50 pilocytic astrocytomas 50 B Raf 50 CIN3 50 DHFR 50 retinoblastoma 50 Notch1 50 inhibit tumor 50 untreated metastatic melanoma 50 thyroid stimulating hormone 50 cetuximab Erbitux 50 papillary renal cell carcinoma 50 colorectal neoplasia 50 neoplastic lesions 50 lung pancreatic 50 mutated gene

Back to home page